Institute of Clinical Chemistry, University Hospital Zurich and University of Zurich, Zurich, Switzerland.
Department of Clinical Biochemistry, Copenhagen University Hospital, Herlev and Gentofte Hospital, Herlev, Denmark.
Eur Heart J. 2023 Apr 21;44(16):1394-1407. doi: 10.1093/eurheartj/ehac605.
Previous interest in high-density lipoproteins (HDLs) focused on their possible protective role in atherosclerotic cardiovascular disease (ASCVD). Evidence from genetic studies and randomized trials, however, questioned that the inverse association of HDL-cholesterol (HDL-C) is causal. This review aims to provide an update on the role of HDL in health and disease, also beyond ASCVD. Through evolution from invertebrates, HDLs are the principal lipoproteins, while apolipoprotein B-containing lipoproteins first developed in vertebrates. HDLs transport cholesterol and other lipids between different cells like a reusable ferry, but serve many other functions including communication with cells and the inactivation of biohazards like bacterial lipopolysaccharides. These functions are exerted by entire HDL particles or distinct proteins or lipids carried by HDL rather than by its cholesterol cargo measured as HDL-C. Neither does HDL-C measurement reflect the efficiency of reverse cholesterol transport. Recent studies indicate that functional measures of HDL, notably cholesterol efflux capacity, numbers of HDL particles, or distinct HDL proteins are better predictors of ASCVD events than HDL-C. Low HDL-C levels are related observationally, but also genetically, to increased risks of infectious diseases, death during sepsis, diabetes mellitus, and chronic kidney disease. Additional, but only observational, data indicate associations of low HDL-C with various autoimmune diseases, and cancers, as well as all-cause mortality. Conversely, extremely high HDL-C levels are associated with an increased risk of age-related macular degeneration (also genetically), infectious disease, and all-cause mortality. HDL encompasses dynamic multimolecular and multifunctional lipoproteins that likely emerged during evolution to serve several physiological roles and prevent or heal pathologies beyond ASCVD. For any clinical exploitation of HDL, the indirect marker HDL-C must be replaced by direct biomarkers reflecting the causal role of HDL in the respective disease.
先前人们对高密度脂蛋白(HDL)的关注集中在其对动脉粥样硬化性心血管疾病(ASCVD)的可能保护作用上。然而,来自遗传研究和随机试验的证据对 HDL 胆固醇(HDL-C)的反比关联提出了质疑,认为其并非因果关系。本综述旨在提供有关 HDL 在健康和疾病中的作用的最新信息,也超越了 ASCVD。通过从无脊椎动物的进化,HDL 是主要的脂蛋白,而载脂蛋白 B 含有的脂蛋白首先在脊椎动物中发展。HDL 像可重复使用的渡轮一样,在不同细胞之间运输胆固醇和其他脂质,但还具有许多其他功能,包括与细胞的交流以及灭活细菌脂多糖等生物危害。这些功能是由整个 HDL 颗粒或由 HDL 携带的独特蛋白质或脂质发挥的,而不是由其作为 HDL-C 测量的胆固醇载量发挥的。HDL-C 测量既不反映胆固醇逆向转运的效率。最近的研究表明,HDL 的功能测量,特别是胆固醇流出能力、HDL 颗粒数量或独特的 HDL 蛋白,比 HDL-C 更能预测 ASCVD 事件。低 HDL-C 水平与传染病、脓毒症期间的死亡、糖尿病和慢性肾病的风险增加有关,这是观察到的,也是遗传上的。此外,只有观察性数据表明低 HDL-C 与各种自身免疫性疾病和癌症以及全因死亡率之间存在关联。相反,极高的 HDL-C 水平与年龄相关性黄斑变性(也与遗传有关)、传染病和全因死亡率的风险增加有关。HDL 包含动态的多分子和多功能脂蛋白,可能在进化过程中出现,以发挥多种生理作用,并预防或治疗 ASCVD 以外的疾病。对于任何对 HDL 的临床利用,必须用直接反映 HDL 在相应疾病中因果作用的直接生物标志物替代间接标志物 HDL-C。